TABLE S1: Best Practice in Medicinal Plant Extract Characterisation online survey questions.

Participant Information Sheet (PIS) Title of Study: Best Practice in Medicinal plant Extract Characterisation Department: UCL School of Pharmacy Name of the Principal Investigator: Prof. Michael Heinrich. Name and Contact Details of the Investigator: Dr. Banaz Jalil (b.jalil@ucl.ac.uk). 1. Invitation Paragraph We would like to invite you to participate in this survey. Before you decide whether you want to take part, it is important for you to read the following information. Please ask us if there is anything that is not clear or you would like more information. Take time to decide whether or not you wish to take part. 2. What is the study's purpose? Our study focuses on defining Best Practice Guidelines for conduction and reporting extract characterisation used in pharmacological, toxicological and clinical/intervention studies. It is for researchers actively involved in projects in such studies. Importantly, we also plan to assess feasibility under different laboratory conditions for this type of phytochemical analysis.

3. What are the possible benefits of taking part? Your views in your role as researchers are essential. We want to gather perspectives, opportunities, and overarching challenges faced in the characterisation of medicinal plant extracts under different laboratory infrastructures globally. Your opinions will help to develop Best Practice Guidelines on how to design, conduct and report the phytochemical analysis in a reproducible and transparent way, as well as defining the requirements needed for defining the plant material/herbal substances, herbal extracts, and herbal medicinal products used in pharmacological, toxicological, and clinical/intervention studies. 4. Will my taking part in this project be kept confidential? No personal identifiable data will be collected. All of the data we collect will be confidential – there will be a participant number attached to your results. However, we will not be able to link this back to your name. **5. Contact for further information** If there is anything that is not clear, or if you would like more information, please do not hesitate to contact us: Prof. Michael **Heinrich and Dr. Banaz Jalil** (please see above). **6. The project** is conducted by a collaborative team of researchers including senior editors of leading journals in the field and is funded through a charitable donation (Fa. Schwabe). Thank you for reading the participant information sheet and for considering taking part in this study.

	 Yes, I have read the participant information sheet, and I agree to participate in the survey study
Pá	age Break

End of Block: Participant Information Sheet (PIS)
Start of Block: Demographic information
Q1 What is your age group?
▼ 21-30 Prefer not to say
Q2 How do you describe your gender?
▼ Male Prefer not to say
Q3 What is the type of organisation do you work in?
O Academia/University
○ Government
O Industry
O Independent Research Centre
Other, please specify
O Prefer not to say

Q4 What is your career level?	
O Ph.D. student/researcher	
O Postdoctoral researcher	
O Lecturer	
Senior Lecturer/Reader	
Professor	
Other, please specify	
O Prefer not to say	

Q5 Which of tapply.	he following best describes your current role/position? Please select all that
	Director/Head of Institute/Department
	Editor In Chief/Associate Editor
	Director/Head of Research Centre
	Head of Research group
	Manager/Supervisor
	Consultant
	Researcher
	Other, please specify
	I do not hold any position
	Prefer not to say

groups used is based on the United Nations geoscheme system. It was devised by the United Nations Statistics Division (UNSD) based on the M49 coding classification (please see above link). Africa - Northern Africa Africa - Sub-Saharan Africa Americas - Latin America and the Caribbean Americas - Northern America Asia - Central Asia Asia - Eastern Asia Asia - South-eastern Asia Asia - Southern Asia Asia - Western Asia Europe - Eastern Europe (including Northern Asia Europe - Western Europe (including the Mediterranean and Northern Europe) Oceania - Australia and New Zealand **End of Block: Demographic information**

Start of Block: Type, and Focus of research as well as Type of extracts used

Q6 Where are you located? e.g., the Continent/Country you are based in*

(*) The division of the countries and territories of the world into regional and subregional

Q7 What type apply.	of research concerning medicinal plants do you conduct? Please select all that
	Pharmacological experiments (in vitro)
	Pharmacological experiments (in vivo)
	Enzyme based pharmacological experiments
	Toxicological experiments
	Clinical/intervention studies
	Other, please specify

clinical/interve	nical/intervention studies? Please select all that apply.	
	The gastrointestinal and biliary system	
	The cardiovascular system	
	The respiratory system	
	The central nervous system	
	The endocrine system	
	The reproductive tract	
	The musculoskeletal system	
	The skin	
	The eye	
	Ear, nose and oropharynx	
	Weight loss	
	Aphrodisiac	
	Stress management	
	Cosmetics	
	Psychoactive	
	Hallucinogen	
	Infectious diseases	

Q8 What is the main focus of your research in terms of pharmacological, toxicological and/or

Anti-cancer activity
Antimicrobial activity
Cytotoxicity activity
Antioxidant activity
Anti-inflammatory activity
Anti-ageing
Other, please specify

that apply.	e main type of extract that you regularly use in your research? Please select all
	Plant material/herbal substances
	Herbal extracts
	Standardised herbal extracts
	Quantified herbal extracts
	Refined herbal extracts
	Herbal extracts used for cosmetic, food and other purposes
	Herbal preparations/products
	Herbal medicinal products
	Other, please specify
End of Block:	Type, and Focus of research as well as Type of extracts used
Start of Block	: Type, Accessibility, and Use of phytochemical techniques, and/or databases
	ny individual projects/studies concerning medicinal plants do you regularly rvise/conduct per year?
O Less th	nan 5 studies
O 5 - 10	studies
O More	than 10 studies

of the extracts	5 ?
O Always	s (all of the studies)
O Most o	of the studies (for about three-quarters of extracts studied)
O About	half of the studies
O Some o	of the studies (for about a quarter of extracts studied)
ONever	(none of the studies)
	ne main type of phytochemical/analytical techniques and/or databases/software access to/regularly use? Please select all that apply.
	Chromatographic techniques
	Spectroscopic techniques
	Network Pharmacology/Biological Network
	Genomics, Proteomic and Metabolomics analysis
	High Content Screening (HCS/HCA) technologies
	Other, please specify
	I do not have access/regularly use any

Q11 For how many of these projects/studies do you conduct a phytochemical characterisation

Q13 How often do you access to the above phytochemical/analytical techniques and/or databases/software?
○ Always
O Most of the time
About half the time
○ Sometimes
O Never
Q14 What is your preferred type of phytochemical/analytical technique and/or database/software you have access/regularly use in your research? Please rank them in order of accessibility/usage from 1 (most preferred) to 5 (least preferred) Chromatographic techniques Spectroscopic techniques Network Pharmacology/Biological Network Genomics, Proteomic and Metabolomics analysis High Content Screening (HCS/HCA) technologies Other, please specify
End of Block: Type, Accessibility, and Use of phytochemical techniques, and/or databases

Start of Block: Challenges and Barriers for medicinal plant extract characterisation

Q15 What do you see (if any) as core barriers to extract characterisation in pharmacological,

toxicological and/or clinical/intervention studies? Please select all that apply. The complexity of medicinal plant components The variability of medicinal plant compositions The difficulty in standardisation of medicinal plant extracts Restricted/limited funding Lack of mandates and guidelines by academic journals Lack of good agricultural practices Lack of laboratory infrastructure Lack of access to latest techniques and technologies Lack of good manufacturing practices Lack of access to online databases and software Lack of time for you as a researcher Lack of trained personnel/training Other, please specify I do not perceive any barriers Q16 Based on your response to question 15, which of the ones you selected is the most important barrier(s)? Please comment in the box below.

	uld help you to overcome the existing barriers in medicinal plant extract on (e.g. pharmacological, toxicological and/or clinical/intervention studies)? all that apply.
	Rigorous and sustainable supply chain of plant material/herbal substances
	Published mandates and guidelines by academic journals
	Platforms for accessing specific collaborative links
	Better equipped laboratory facilities
	Accessible online databases and software
	Other, please specify
	Nothing
	you think could be improved in pharmacological, toxicological and/or ention studies using medicinal plant extracts? Please comment in the box below.
Q19 What do	you think needs to be improved in medicinal plants research more generally?
Other comme	ents/suggestions, please write them down in here

	
End of Block: Challenges and Barriers for medicinal plant extract characterisa	tion